Key Recommendations - Strong downstream demand has led to further price increases in refrigerants, with prices for R32, R125, and R134a rising by 2.56%, 7.04%, and 11.43% respectively as of November 29, 2024 [8][9] - The 2025 refrigerant quota draft indicates an increase in R32 supply, suggesting that refrigerant prices will continue to rise in the long term [9] - December saw a continuous increase in household appliance sales and production, supporting strong refrigerant demand, with air conditioning production expected to remain high [10] Asset Allocation Outlook - Domestic asset performance in 2024 has shown equities outperforming commodities, bonds, and other asset classes [11] - The outlook for 2025 suggests a stable RMB exchange rate with limited fluctuations, while the bond market is expected to remain strong [12][13] - The commodity market is anticipated to show resilience, with oil prices expected to fluctuate between $55 and $80 per barrel next year [13] Industry Insights - The chemical industry is at a cyclical low, with cash flow improvements expected to balance capital expenditures and dividends [16] - The high-end manufacturing sector is seeing increased domestic market share due to the gradual realization of domestic substitutes for key components [16] - The financial sector is characterized by low valuations and high dividend yields, with a focus on strengthening leading securities firms through mergers and acquisitions [16] Economic and Policy Outlook - The report highlights the Chinese government's strong commitment to economic growth, with expectations for a stable recovery supported by various monetary and fiscal policies [19][20] - The macroeconomic environment is expected to stabilize, with increased corporate profitability likely to enhance the value of listed companies [20] - The report emphasizes the importance of cooperation in building an open global economy, with a focus on innovation and technology as key growth drivers [28]

Investment Rating - The report does not explicitly state an investment rating for the non-banking financial industry. Core Insights - The report emphasizes the restructuring and transformation of the non-banking financial industry under the guidance of policies aimed at strong regulation, risk prevention, and promoting high-quality development [1]. Summary by Sections 1. 2024 Review: Market and Performance Recap - As of the end of November, the securities sector saw a return of +35% and the insurance sector +36%, with excess returns exceeding 20 percentage points [3]. - Overall performance in the first three quarters of 2024 showed a revenue decline of 3% year-on-year and a net profit decline of 6%, with significant pressure on brokerage and investment banking businesses [5][6]. 2. Policy Mainline: Strong Regulation, Risk Prevention, and Promotion of High-Quality Development - The new "National Nine Articles" for capital markets aims to establish a framework for development over the next five years, focusing on direct financing and enhancing market functions [20][21]. - The insurance sector's new "National Ten Articles" expands regulatory focus from scale to quality, emphasizing market access, ongoing supervision, and risk prevention [25]. 3. Trends in the Securities Sector - **Trend 1**: Deepening investment-side reforms, with expectations for increased long-term capital inflows. The number of new A-share accounts opened in October 2024 reached 6.85 million, indicating heightened market activity [32]. - **Trend 2**: Cautious equity financing, with IPO and refinancing volumes down 83.7% and 71.9% respectively, while the M&A market is heating up due to regulatory support [47]. 4. Trends in the Insurance Sector - **Trend 1**: Expansion of new business value (NBV) growth, driven by a surge in new policy sales following interest rate adjustments [10]. - **Trend 2**: Significant improvement in total investment returns, with major insurance companies reporting substantial increases in net profit [14]. 5. Investment Recommendations - The report suggests focusing on sectors with strong regulatory support and potential for high-quality growth, particularly in the context of ongoing reforms and market restructuring [31].

Export Data - In November 2024, exports amounted to $312.3 billion, the highest since September 2022, but the year-on-year growth rate fell to 6.7% from 12.7% in October[1][2] - Imports in November 2024 decreased by 3.9% year-on-year, with an absolute value of $214.87 billion, indicating a weak domestic demand[1][4] - The trade surplus expanded to $97.443 billion in November, compared to the previous value[1] External Demand and Trade Relations - External demand remains uncertain, with the global manufacturing PMI at 50.0, while the US ISM manufacturing PMI is at 48.4, indicating contraction[3] - Exports to the EU saw a significant decline, with growth dropping by 5.49 percentage points to 7.23% due to low economic sentiment and tariff impacts[3][4] - Exports to the US, ASEAN, and Japan also experienced slight declines, with year-on-year growth rates of 8.0%, 14.9%, and 6.35% respectively[3] Product-Specific Trends - Key products like steel, automotive parts, and medical instruments showed significant declines in export growth, likely influenced by recent tariff implementations[4] - Technical products such as automatic data processing equipment and LCD panels saw slight growth, contrasting with the overall trend[4] Policy Implications - The report emphasizes the need for policy measures to boost domestic demand, as current levels remain weak despite some positive signals in manufacturing PMI[4][5] - The upcoming political meetings are expected to focus on expanding domestic demand and implementing counter-cyclical adjustments[2]

Key Recommendations - The trend of domestic substitution continues, creating a new growth curve in the automation equipment sector. The report emphasizes the importance of capturing domestic sales opportunities and advancing the localization of automation equipment. The automation equipment sector, classified under machinery, includes sub-sectors such as robotics, industrial control equipment, and laser equipment. Despite a slowdown in growth rates for major sub-sectors since 2021, there are still several industries in China experiencing high fixed asset investment growth this year. The report anticipates that policies promoting equipment upgrades will drive demand for automation solutions [7][8]. - The report suggests that while short-term demand fluctuations may intensify price competition, the trends of digital intelligence upgrades and domestic substitution are expected to persist. Leading domestic companies are now capable of providing comprehensive automation solutions and consulting services to overseas clients, which aligns with the growth of Chinese manufacturing abroad. Key companies to watch include Huichuan Technology and Estun Automation [8][9]. Economic News - The report highlights that the sales of new commercial housing in 30 cities improved in November, with transaction area increasing by 19.8% year-on-year, marking two consecutive months of improvement. Additionally, the pace of debt repayment has accelerated, with over 1.9 trillion yuan in refinancing special bonds replacing hidden debts as of December 5 [9][10]. - The phenomenon of "export grabbing" is expected to support external demand in the short term, particularly in light of potential tariffs from the new U.S. administration. However, current shipping rates have not yet reflected this trend [10]. - The report notes that the profits of industrial enterprises at or above designated size saw a narrowing year-on-year decline to -10.0% in October, indicating a low-level improvement in profit margins [12]. A-Share Market Commentary - The report indicates that the Shanghai Composite Index closed up 1.05% at 3404 points, with significant technical progress as it broke above the downward trend line since October 8, 2024. The market is showing active buying interest, although large-scale capital outflows were noted [24][25]. - The Shenzhen Component Index and the ChiNext Index also saw gains, with increases of 1.47% and 2.05%, respectively. The report emphasizes the importance of monitoring volume and price indicators as the indices approach key resistance levels [25][26]. Market Data - As of December 6, 2024, the financing balance stood at 185.48 billion yuan, with a slight increase of 71.94 million yuan. The report also provides various interest rates, including a 10-year government bond yield of 1.9539% and a 1-year LPR of 3.1% [30].

Exchange Rate Outlook - The exchange rate is expected to show resilience, with a projected fluctuation range of 7.10 to 7.40 against the US dollar[51] - The offshore RMB funding rates have decreased, indicating reduced pressure on the exchange rate[47] - The USD/CNY exchange rate swap points are expected to fluctuate, with a six-month period showing a value of -1082 pips[48] Bond Market Analysis - The bond market has experienced a significant bull run, with 10-year and 30-year government bond yields dropping to 1.85% and 2.05%, respectively, a decline of 70 basis points and 78 basis points within the year[53] - Government bond net financing reached CNY 4.15 trillion and local government bond net financing was CNY 6.7 trillion as of December 7, 2024[54] - The demand for bonds has increased among commercial banks and insurance institutions, with bond investments rising to 45.4% of insurance funds by the end of 2023[62] Gold Market Insights - The gold market may see a new allocation window, with potential for new highs due to favorable economic conditions[51] Risk Factors - The report highlights risks associated with external uncertainties, particularly regarding US-China relations and potential tariff impacts from the Trump administration[38] - The inversion of the US-China 10-year bond yield spread remains significant at 220 basis points, indicating ongoing market volatility[43]

Economic Overview - The nominal GDP growth rates for the first three quarters of 2024 were 3.97%, 4.06%, and 4.04%, with a cumulative rate of 4.02%, indicating pressure to achieve the annual target of 5%[30] - The GDP deflator index has been negative for six consecutive quarters, reflecting a mismatch between nominal and real GDP growth rates[31] Consumer and Investment Trends - Retail sales growth for the first ten months of 2023 was 3.5%, with a slight recovery in October to 4.8%, but still below the average of 9.4% from 2016 to 2019[38] - Fixed asset investment growth has slightly declined to 3.4% in October 2024, with manufacturing investment at 9.3% and real estate investment showing a significant decline of -10.3%[49] Policy and Market Dynamics - The government has implemented a series of monetary and fiscal policies to stimulate the economy, including interest rate cuts and support for the real estate sector[84] - The real estate market remains under pressure, with cumulative investment growth at -10.3% as of October 2024, although recent policies may help mitigate this decline[63] External Factors and Risks - Exports showed resilience with a year-on-year growth of 6.7% in November 2023, but global manufacturing PMI indicates a downward trend, suggesting potential challenges ahead[72] - The banking sector has faced significant challenges, with several bank failures in 2023 and ongoing concerns about the stability of the financial market[15]

Economic Cycle Insights - The current economic cycle is in the early stages of recovery, characterized by a decline in money supply and a gradual improvement in corporate profits[3] - Since 2000, the compound annual growth rates (CAGR) for crude oil, gold, and copper prices have been 4.2%, 9.7%, and 6.8% respectively, indicating a strong correlation between commodity prices and economic cycles[11] Commodity Price Trends - Commodity prices are closely linked to inflation, with the Consumer Price Index (CPI) and Producer Price Index (PPI) being lagging indicators[4] - The CRB index, which tracks various economic-sensitive commodities, often sees price increases towards the end of the Federal Reserve's interest rate hike cycles[14] Future Projections - Global GDP growth is projected to stabilize at 3.2% for both 2024 and 2025, with oil prices expected to fluctuate between $55 and $80 per barrel in 2025[68] - The global steel demand is forecasted to decline by 0.9% in 2023, with a potential recovery expected by 2025[49] Investment Strategies - The report suggests a re-evaluation of asset allocation strategies, emphasizing the importance of understanding the cyclical nature of commodities and their impact on corporate profitability[24] - The anticipated recovery in industrial profits is supported by a projected 2.1% decline in producer prices year-on-year, indicating potential for future price increases[36] Risk Considerations - The report highlights risks associated with rapid commodity price increases, which may lead to stock price corrections if sustainability is questioned[36] - The divergence in manufacturing and service sector performance may pose challenges for economic stability, particularly if manufacturing weakness affects service sector growth[56]

Investment Rating - The report maintains a positive outlook on the refrigerant industry, suggesting that the industry is expected to maintain a high level of prosperity due to strong downstream demand and price increases [5][6][83]. Core Insights - As of November 29, 2024, the prices of refrigerants R32, R125, and R134a have increased by 2.56%, 7.04%, and 11.43% respectively compared to the end of October, with R22 also seeing a price increase of 3.23% [5][9]. - The supply of R32 is expected to increase due to the draft for the 2025 refrigerant quota distribution, which will maintain upward pressure on refrigerant prices in the long term [5][6]. - The demand for refrigerants is supported by the rising production of household air conditioners, with production figures for December 2024 to February 2025 showing significant year-on-year growth [6][52]. Summary by Sections 1. Core Insights - The report highlights that the price gap for refrigerants has increased, with R22 prices rising significantly, indicating a strong market demand [5][27]. - The production quotas for second-generation refrigerants are being reduced, while third-generation refrigerants will maintain their production levels, leading to a tightening supply-demand relationship [5][6]. 2. Refrigerant Tracking - The report provides detailed tracking of refrigerant prices and production rates, noting that the production rates for R32, R134a, and R125 have shown fluctuations, with R32 experiencing a decrease in inventory levels [19][21]. - The total inventory of R22 has been on a long-term decline, indicating a tightening market [38][36]. 3. Fluoropolymer Insights - The prices of fluoropolymers such as PTFE, PVDF, and HFP are currently low due to rapid capacity increases and slowing demand growth [61]. - The report notes a significant drop in the production of fluoropolymers, with production figures for November 2024 showing declines compared to previous years [68][69]. 4. Investment Recommendations - The report recommends focusing on leading companies in the refrigerant industry and those with a complete industrial chain, such as Juhua Co., Ltd. and Sanmei Co., Ltd., as well as companies related to fluorochemical raw materials [6][83].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry Core Insights - The pharmaceutical and biotechnology industry has shown weak growth and declining profitability in 2024, with A-share listed companies in the industry reporting a total revenue of 1.814 trillion yuan, a year-on-year decrease of 0.39%, and a net profit of 145.04 billion yuan, down 9.01% year-on-year [3][45] - The industry has faced challenges from macroeconomic conditions, policy changes, and anti-corruption measures, leading to a 9.29% decline in the pharmaceutical and biotechnology sector, which has underperformed compared to the broader market [3][13] - Looking ahead, the industry is expected to stabilize and recover due to factors such as population aging, the implementation of supportive policies for innovative drugs and medical devices, and the normalization of procurement processes [3][45] Summary by Sections Market Review - From January 1 to November 30, 2024, the pharmaceutical and biotechnology sector experienced a decline of 9.29%, ranking last among 31 industry classifications [11][13] - The sector's performance has been significantly impacted by various factors, including anti-corruption policies and slow progress in procurement processes [3][11] Industry Overview - The pharmaceutical manufacturing industry reported a revenue of 1.84 trillion yuan in the first three quarters of 2024, with a slight year-on-year increase of 0.20%, while total profits decreased by 0.40% [38] - The overall industry is gradually stabilizing despite the challenges posed by policy changes and market conditions [38][41] Subsector Analysis - Among the six secondary sub-industries, only the chemical pharmaceutical sector saw an increase, with a growth rate of 2.93%, while the biological products sector experienced the largest decline at 22.31% [17] - The report highlights specific companies such as Kelun Pharmaceutical, Betta Pharmaceuticals, and Teva Biopharmaceuticals as notable performers within the sector [5] Valuation and Market Capitalization - As of November 30, 2024, the total market capitalization of the A-share pharmaceutical and biotechnology sector reached 6.2 trillion yuan, with 496 listed companies [19] - The sector's price-to-earnings (PE) ratio stood at 27.8 times, representing a 135% premium over the CSI 300 index, indicating a relatively low valuation compared to historical levels [25][30] Future Outlook - The report suggests three main investment themes for 2025: innovative growth companies with new product launches, companies entering a new development cycle after overcoming negative impacts, and firms with strong merger and acquisition potential [3] - Investment opportunities are identified in segments such as innovative drugs, medical devices, and healthcare services [3]

晨 会 纪 要 [Table_Report] [Table_Reportdate] 2024年12月10日 [晨会纪要 Table_NewTitle] 20241210 [证券分析师： Table_Authors] 张季恺S0630521110001 zjk@email.com.cn 联系人： 陈伟业 cwy@longone.com.cn [table_main] 重点推荐 ➢ 1.行业需求稳增，关注高景气赛道——美容护理行业2025年投资策略 ➢ 2.挖机内销增幅扩大，国产品牌bamua展大展风采——机械设备行业简评 ➢ 3.轻舟已过，耐心布局——医药生物行业2025年度策略 ➢ 4.加强超常规逆周期调节——国内观察：2024年12月政治局会议点评 财经要闻 ➢ 1.李强同主要国际经济组织负责人举行"1+10"对话会 ➢ 2.11月CPI小幅回落 PPI降幅收窄 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 晨会纪要 正文目录 1. 重点推荐....................................................... ...